thumbnail image
  • Home
  • About us  
    • Company
    • CORE TEAM
    • QUALITY UNIT
    • BUSINESS
  • Services  
    • GENERAL TOXICOLOGY
    • DART
    • GENETIC TOXICOLOGY
    • SAFETY PHARMACOLOGY
    • PK/TK
    • EFFICACY STUDY
    • OPHTHALMIC LAB
    • CARCINOGENES
    • Project Management System for Client
  • Laboratories  
    • PATHOLOGY LAB
    • CLINICAL LAB
    • BIO-ANALYSIS
    • TEST ARTICLE LAB
  • Animal Welfare  
    • Animal welfare
  • News&Events
  • Home
  • About us
    • Company
    • CORE TEAM
    • QUALITY UNIT
    • BUSINESS
  • Services
    • GENERAL TOXICOLOGY
    • DART
    • GENETIC TOXICOLOGY
    • SAFETY PHARMACOLOGY
    • PK/TK
    • EFFICACY STUDY
    • OPHTHALMIC LAB
    • CARCINOGENES
    • Project Management System for Client
  • Laboratories
    • PATHOLOGY LAB
    • CLINICAL LAB
    • BIO-ANALYSIS
    • TEST ARTICLE LAB
  • Animal Welfare
    • Animal welfare
  • News&Events
    •  

       

       

       

    • About Us

      WestChina-Frontier PharmaTech (WCFP) was founded in February 2000. The facility was also known as National Chengdu New Drug Safety Evaluation Center. The company provides pre-clinical GLP drug safety and efficacy evaluation. The company is OECD, CAP, NMPA-GLP and AAALAC accredited, and has successfully passed FDA inspection.

       

      WCFP has a staff of 580, including 7 NMPA New Drug Reviewers. WCFP also has a SQARQAP-GLP certified expert, an AAALAC expert, several national-class pathologists and more than 40 well experienced animal technicians.WCFP's GLP animal facility is 26000m2 large. It is able to conduct 130 studies (on rat, mouse, rabbit, canine, guinea pig and NHP) simultaneously.

       

       

      WCFP can submit laboratory data to both NMPA and FDA, depending on clients' needs, and has so far submitted data for over 60 new drugs to FDA. WCFP employs Pristima® LIMS system developed by Xybion for electronic data collection, processing and archiving to ensure GLP data integrity. WCFP is able to provide study data in SEND format in compliance with FDA's new regulation.

       

       

    • Services

      General Toxicology

      DART

      Genetic Toxicology

      Safety Pharmacology

         

      PK / TK

      Efficacy Study

      Ophthalmic Lab

       

       

      Carcinogenes

    • Company News

    • 【喜讯】

      2017年4月17日-04月21日

      成都安评中心顺利通过美国FDA GLP现场检査

      [CAP]公司以零缺陷通过CAP检查认证

      2014年7月16日

      华西海圻医药科技有限公司于2014年7月16日接受了CAP

       

      【读片会圆满召开】

      2016年3月4日

      2016年西南片区毒性病理学研讨会暨圆满召开

      【病理学研讨会】

      2015年5月5日

      2015年第四届国际毒性病理学研讨会圆满结束

    • Strategic Alliance

    • Partners

    • Contact Us

      蜀ICP备11014334号-1

      (+86) 028 -8515-4334 转800

      Phone

      service@glpcd.com

      E-mail

      成都新药安评中心

      WeChat

      所有文章
      ×
      成都华西海圻医药科技有限公司(English)
      成都华西海圻医药科技有限公司,国家成都新药安全性评价中心
      https://user-assets.sxlcdn.com/images/397921/Fuuup8iHbnSRXKbrJb7f8RgJ3o2r.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png
      Cookie的使用
      我们使用cookies来确保流畅的浏览体验。若继续,我们认为你接受使用cookies。
      了解更多